BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22768165)

  • 21. Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates.
    Khanna M; Rady H; Dai G; Ramsay AJ
    Vaccine; 2021 Mar; 39(12):1780-1787. PubMed ID: 33632562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis.
    Dey B; Jain R; Gupta UD; Katoch VM; Ramanathan VD; Tyagi AK
    PLoS One; 2011; 6(8):e23360. PubMed ID: 21858087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
    Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
    Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Boosting BCG-primed mice with chimeric DNA vaccine HG856A induces potent multifunctional T cell responses and enhanced protection against Mycobacterium tuberculosis.
    Ji P; Hu ZD; Kang H; Yuan Q; Ma H; Wen HL; Wu J; Li ZM; Lowrie DB; Fan XY
    Immunol Res; 2016 Feb; 64(1):64-72. PubMed ID: 26111521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice.
    Wang C; Chen Z; Fu R; Zhang Y; Chen L; Huang L; Li J; Shi C; Fan X
    Med Microbiol Immunol; 2011 Aug; 200(3):165-75. PubMed ID: 21340709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new recombinant BCG vaccine induces specific Th17 and Th1 effector cells with higher protective efficacy against tuberculosis.
    da Costa AC; Costa-Júnior Ade O; de Oliveira FM; Nogueira SV; Rosa JD; Resende DP; Kipnis A; Junqueira-Kipnis AP
    PLoS One; 2014; 9(11):e112848. PubMed ID: 25398087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Mycobacterial Ribosomal Proteins as Targets for CD4
    Kennedy SC; Johnson AJ; Bharrhan S; Lindestam Arlehamn CS; Xu J; Garforth SJ; Chan J; Jacobs WR; Sette A; Almo SC; Porcelli SA
    Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29891545
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.
    Lu J; Wang C; Zhou Z; Zhang Y; Cao T; Shi C; Chen Z; Chen L; Cai C; Fan X
    Clin Dev Immunol; 2011; 2011():617892. PubMed ID: 21461375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced protective efficacy against Mycobacterium tuberculosis afforded by BCG prime-DNA boost regimen in an early challenge mouse model is associated with increased splenic interleukin-2-producing CD4 T-cell frequency post-vaccination.
    Kang H; Yuan Q; Ma H; Hu ZD; Han DP; Wu K; Lowrie DB; Fan XY
    Immunology; 2014 Dec; 143(4):661-9. PubMed ID: 24965530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose.
    Aagaard C; Hoang TT; Izzo A; Billeskov R; Troudt J; Arnett K; Keyser A; Elvang T; Andersen P; Dietrich J
    PLoS One; 2009 Jun; 4(6):e5930. PubMed ID: 19529771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multiple T cell epitope comprising DNA vaccine boosts the protective efficacy of Bacillus Calmette-Guérin (BCG) against Mycobacterium tuberculosis.
    Maurya SK; Aqdas M; Das DK; Singh S; Nadeem S; Kaur G; Agrewala JN
    BMC Infect Dis; 2020 Sep; 20(1):677. PubMed ID: 32942991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal immunization with peptide-based immunogenic complex enhances BCG vaccine efficacy in a murine model of tuberculosis.
    Kumar S; Bhaskar A; Patnaik G; Sharma C; Singh DK; Kaushik SR; Chaturvedi S; Das G; Dwivedi VP
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33444288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
    Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
    Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.
    Zhang M; Dong C; Xiong S
    Hum Vaccin Immunother; 2017 Apr; 13(4):816-822. PubMed ID: 27960596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Promising Listeria-Vectored Vaccine Induces Th1-Type Immune Responses and Confers Protection Against Tuberculosis.
    Yin Y; Lian K; Zhao D; Tao C; Chen X; Tan W; Wang X; Xu Z; Hu M; Rao Y; Zhou X; Pan Z; Zhang X; Jiao X
    Front Cell Infect Microbiol; 2017; 7():407. PubMed ID: 29034213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis.
    Nandakumar S; Kannanganat S; Dobos KM; Lucas M; Spencer JS; Amara RR; Plikaytis BB; Posey JE; Sable SB
    Sci Rep; 2016 May; 6():25837. PubMed ID: 27173443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.
    Masonou T; Hokey DA; Lahey T; Halliday A; Berrocal-Almanza LC; Wieland-Alter WF; Arbeit RD; Lalvani A; von Reyn CF
    PLoS One; 2019; 14(5):e0217091. PubMed ID: 31120957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.